{"entity":{"id":"jean-pascal-machiels","kind":"person","name":"Jean-Pascal Machiels","aka":[],"tldr":"Brussels oncologist who led KEYNOTE-412, the trial that tested adding pembrolizumab to chemoradiotherapy for locally advanced head and neck cancer.","summary":"Jean-Pascal Machiels heads medical oncology at Cliniques universitaires Saint-Luc in Brussels and chairs the EORTC head and neck cancer group. He was first author of the 2024 Lancet Oncology report of KEYNOTE-412, the phase 3 trial of pembrolizumab with and after cisplatin-based chemoradiotherapy in locally advanced head and neck squamous-cell carcinoma, which did not reach statistical significance for event-free survival, and of the European guidelines for the disease.","asOf":"2026-09-18","links":[],"tags":["head-and-neck","immunotherapy","trialist"],"related":[],"cancers":["hpv-negative-head-and-neck-cancer","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["king-albert-ii-cancer-institute"],"pathways":[],"terms":[],"trials":["keynote-412"],"people":[],"bottlenecks":[],"keyPapers":["paper-jean-pascal-machiels-lancet-2019","paper-jean-pascal-machiels-ann-oncol-2020","paper-jean-pascal-machiels-ann-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Cliniques universitaires Saint-Luc, Brussels","institutionId":"king-albert-ii-cancer-institute","specialisms":["Head and neck cancer","Chemoradiotherapy with immunotherapy","Early-phase trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Machiels%5BAuthor%5D"}],"papers":[{"title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","journal":"The Lancet","year":2019,"url":"https://doi.org/10.1016/s0140-6736(18)31999-8","doi":"10.1016/s0140-6736(18)31999-8","note":"Europe PMC author record matched by affiliation (King Albert II Cancer Institute, Cliniques universitaires Saint-Luc); 1354 citations on Europe PMC."},{"title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2020,"url":"https://doi.org/10.1016/j.annonc.2020.07.011","doi":"10.1016/j.annonc.2020.07.011","note":"Europe PMC author record matched by affiliation (King Albert II Cancer Institute, Cliniques universitaires Saint-Luc); 672 citations on Europe PMC."},{"title":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up †","journal":"Annals of Oncology","year":2021,"url":"https://doi.org/10.1016/j.annonc.2020.12.007","doi":"10.1016/j.annonc.2020.12.007","note":"Europe PMC author record matched by affiliation (King Albert II Cancer Institute, Cliniques universitaires Saint-Luc); 332 citations on Europe PMC."}]},"route":"/people/jean-pascal-machiels/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"hpv-negative-head-and-neck-cancer","kind":"cancer","name":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","route":"/cancers/hpv-negative-head-and-neck-cancer/"}],"institution":[{"id":"king-albert-ii-cancer-institute","kind":"institution","name":"King Albert II Cancer Institute, Cliniques universitaires Saint-Luc","route":"/institutions/king-albert-ii-cancer-institute/"}],"trial":[{"id":"keynote-412","kind":"trial","name":"KEYNOTE-412","route":"/trials/keynote-412/"}],"paper":[{"id":"paper-jean-pascal-machiels-ann-oncol-2021","kind":"paper","name":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up †","route":"/key-papers/paper-jean-pascal-machiels-ann-oncol-2021/"},{"id":"paper-jean-pascal-machiels-lancet-2019","kind":"paper","name":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","route":"/key-papers/paper-jean-pascal-machiels-lancet-2019/"},{"id":"paper-jean-pascal-machiels-ann-oncol-2020","kind":"paper","name":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-jean-pascal-machiels-ann-oncol-2020/"}]}}